EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Development of Integrin Targeting Chimeras (ITACs) for the Lysosomal Degradation of Extracellular Proteins

Yaxian Zhou, Yaxian Liao, Yuan Zhao, Weiping Tang iD

ChemMedChem · 16.12.2024 · 19 (24)

DOI: 10.1002/cmdc.202300643 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 29.10.2024. Verfasst von Yaxian Zhou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Lachman Institute of Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, 53705, USA. Hauptthemen laut MEDLINE: Lysosomes, Integrins. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIGMS NIH HHS, University of Wisconsin - Madison Office of the Vice Chancellor for Research and Graduate Education, Wisconsin Alumni Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The emerging of lysosomal targeting chimera (LYTAC) expands the field of targeted protein degradation (TPD) to include the extracellular proteins for precise depletion. However, most of the reported LYTACs either induce ubiquitous degradation of the protein of interest (POI) in a broad range of tissues or specifically target liver cells. More tissue‐selective degraders are highly desirable. Herein, we describe the development of cyclic RGD (cRGD) peptide‐antibody conjugates as a novel class of integrin targeting chimeras (ITACs) with potential cancer selectivity. Our results indicate that the ITACs are able to recruit integrin to induce the degradation of both soluble and membrane targets in the lysosome. We observed higher efficiency of ITACs on degrading membrane protein in cancer cells, providing a promising platform for cancer‐selective TPD strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LysosomesIntegrinsHumansPeptides, CyclicMolecular StructureCell Line, TumorImmunoconjugatesProteolysisDose-Response Relationship, Drug

Stichwörter der Autor:innen

Cancer selectivityDegradersIntegrinLYTAC

Substanzen

IntegrinsPeptides, Cycliccyclic arginine-glycine-aspartic acid peptideImmunoconjugates

Autor:innen und Institutionen

  • Lachman Institute of Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, 53705, USA.
  • Department of Chemistry, University of Wisconsin-Madison, Madison, WI, 53706, USA.

ORCID-Profile: Weiping Tang

Förderung

  • NIGMS NIH HHS
  • University of Wisconsin - Madison Office of the Vice Chancellor for Research and Graduate Education
  • Wisconsin Alumni Research Foundation
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Zhou, Y., Liao, Y., Zhao, Y., & Tang, W. (2024). Development of Integrin Targeting Chimeras (ITACs) for the Lysosomal Degradation of Extracellular Proteins. ChemMedChem, 19(24). https://doi.org/10.1002/cmdc.202300643

Vancouver

Zhou Y, Liao Y, Zhao Y, Tang W. Development of Integrin Targeting Chimeras (ITACs) for the Lysosomal Degradation of Extracellular Proteins. ChemMedChem. 2024;19(24). doi:10.1002/cmdc.202300643

BibTeX
@article{Zhou2024,
  author = {Zhou, Yaxian and Liao, Yaxian and Zhao, Yuan and Tang, Weiping},
  title = {Development of Integrin Targeting Chimeras (ITACs) for the Lysosomal Degradation of Extracellular Proteins},
  journal = {ChemMedChem},
  year = {2024},
  volume = {19},
  number = {24},
  doi = {10.1002/cmdc.202300643}
}
Kostenlos starten →